Inside MedSpa — Daily Brief, 2026-06-26
The few things that actually moved in medical aesthetics — distilled. The headlines are free. The so-what is for subscribers.
1Skinvive by Juvéderm FDA-approved for neck lines—new revenue stream and competitive pressure
What happenedFDA approved Skinvive by Juvéderm for improvement of neck appearance and lines. This is a new indication for the Juvéderm family, expanding the product portfolio beyond traditional facial injectables.
2Restylane Contour FDA-approved for temple hollowing—new indication expands filler market
What happenedGalderma received FDA approval for Restylane Contour for correction of temple hollowing, a new indication beyond its prior approvals for lip and cheek augmentation.
3RHA Dynamic Volume FDA-approved for midface augmentation—third major filler indication in months
What happenedFDA cleared RHA Dynamic Volume for midface augmentation and age-related volume loss, adding to a wave of new filler indications across the market.
4AbbVie Allergan Aesthetics files multiple material events—pricing/rebate changes likely imminent
What happenedAbbVie filed three SEC 8-K material events (April 29, May 12, June 22, 2026) related to Allergan Aesthetics, Botox, Juvéderm, and the Allē loyalty program, signaling significant business changes.
5GLP-1 weight-loss drugs confirmed to cause facial fat loss—new treatment opportunity and patient concern
What happenedMedical aesthetics industry leaders have confirmed that GLP-1 weight-loss drugs (such as semaglutide) cause facial fat loss, a side effect now known as 'semaglutide face.'
This is one morning. Get it every morning.
The full brief — what each item means for your practice and exactly what to do about it — lands in your inbox daily. $20 a month. Never be the last to know.
Get the daily brief — $20/mo